Dana-Farber Cancer Institute | Strategic Alliance Partners

January 16, 2024

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

January 16, 2024

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

January 16, 2024

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma.

January 14, 2024

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

January 11, 2024

The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.

January 11, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.

January 11, 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

January 10, 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

January 03, 2024

Sarah Sammons, MD, discusses the goals of treating patients with breast cancer who present with active vs stable brain metastasis.

January 03, 2024

A fascination with laboratory research paired with hard work and dedication led to Nikhil C. Munshi, MD, becoming a pioneer in multiple myeloma treatment.

January 02, 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

January 02, 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

January 02, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

December 31, 2023

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

December 29, 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

December 28, 2023

Researchers at Dana-Farber Cancer Institute found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

December 27, 2023

With perseverance, compassion, and energy, Ann H. Partridge, MD, MPH, has devoted her career to shrinking the gaps in research and care for young women with breast cancer and improving their outcomes and quality of life along the way.

December 24, 2023

Researchers at Dana-Farber Cancer Institute have found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

December 22, 2023

Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.